Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | F2RL1 | P55085 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 3/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19937820 | 0.86 | ALDH1A1 (0.53) | ALDH1A1HTTGAAF2RL1MAPT | |
| SCHEMBL30865737 | 0.84 | NOTUM (0.52) | ALDH1A1HTTGAAF2RL1MAPT | |
| SCHEMBL18559621 | 0.79 | MAPT (0.47) | ALDH1A1HTTMAPTL3MBTL1NOTUM | |
| SCHEMBL2963534 | 0.79 | MAPT (0.54) | ALDH1A1HTTGAAMAPTL3MBTL1 | |
| SCHEMBL2972016 | 0.77 | ALDH1A1 (0.54) | ALDH1A1HTTGAAMAPTL3MBTL1 | |
| SCHEMBL23717773 | 0.76 | ALDH1A1 (0.53) | ALDH1A1HTTGAAF2RL1MAPT | |
| SCHEMBL19154820 | 0.75 | ALDH1A1 (0.41) | ALDH1A1HTTGAAMAPTSMN1; SMN2 | |
| SCHEMBL5716060 | 0.75 | ALDH1A1 (0.56) | ALDH1A1HTTGAAF2RL1MAPT | |
| Hydrochloric Acid SCHEMBL15018127 | 0.73 | ALDH1A1 (0.59) | ALDH1A1HTTGAAF2RL1MAPT | |
| SCHEMBL5715880 | 0.73 | ALDH1A1 (0.59) | ALDH1A1HTTGAAF2RL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577374-B2 | Bruton's tyrosine kinase inhibitors | BTK, ABL1, SYK | ALDH1A1 4783/4885HTT 3688/4885GAA 1670/4885 |
| US-20180065974-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | ALDH1A1 4783/4885HTT 3688/4885GAA 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.